Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Radiation Oncology›Clinical Question·Updated Apr 17, 2026·v1

SBRT vs Surgery in Early Stage NSCLC

The choice between SBRT and surgery for early-stage NSCLC depends on medical operability. Lobectomy remains the standard for fit patients, while SBRT is the standard for inoperable patients. High-risk patients require multidisciplinary evaluation to choose between sublobar resection and SBRT.

High Evidence7 references·1,548 words·7 min read·v1
NSCLCSBRTSABRThoracic SurgeryRadiation OncologyLung Cancer
The management of early-stage (Stage I) non-small-cell lung cancer (NSCLC) has evolved from a surgery-only paradigm to a nuanced, risk-stratified approach. While anatomical lobectomy with lymph node dissection remains the gold standard for medically fit patients, stereotactic body radiation therapy (SBRT)—also known as stereotactic ablative radiotherapy (SABR)—has established itself as the definitive standard of care for medically inoperable patients. The clinical challenge lies in the 'gray zone' of borderline-operable or high-risk patients, where the trade-offs between the superior local control of surgery and the lower acute toxicity of SBRT must be weighed. This decision is increasingly guided by multidisciplinary teams (MDT) incorporating thoracic surgeons, radiation oncologists, and pulmonologists to optimize survival and quality of life in an aging population often identified through lung cancer screening programs.

Board Review — High Yield

  • •SABR vs SBRT — These terms are synonymous; SABR (Stereotactic Ablative Radiotherapy) is often preferred internationally to emphasize the ablative intent.
  • •The 'No-Fly Zone' — Refers to the area within 2 cm of the proximal bronchial tree where high-dose SBRT (3-fraction) is avoided due to risks of bronchial necrosis or fistula.
  • •Local Control — SBRT typically achieves local control rates of >90%, which is comparable to surgical resection in most retrospective series.
  • •Nodal Staging — The primary disadvantage of SBRT compared to surgery is the lack of pathological nodal assessment, leading to a risk of under-treating occult N1/N2 disease.
  • •Radiation Pneumonitis — The most common symptomatic toxicity of SBRT, usually presenting 2-6 months post-treatment with cough and dyspnea.
  • •FEV1/DLCO Thresholds — Values <50% predicted identify 'high-risk' surgical candidates; <30% often identifies 'inoperable' candidates.
  • •STARS and ROSEL Trials — Pooled analysis of these small randomized trials suggested SBRT might have superior survival to surgery, though the data is controversial due to low accrual.
  • •Standard SBRT Dose — 54 Gy in 3 fractions is a classic regimen for peripheral Stage I tumors.

Deep Dive — Evidence Details

References

  1. [1]

    Edwards JP, Datta I, Hunt JD et al.. “Forecasting the impact of stereotactic ablative radiotherapy for early-stage lung cancer on the thoracic surgery workforce.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2016). PMID: 26796110 ↗

    L5OTHERCited in: Special Populations: Operable vs. Inoperable Patients
  2. [2]

    Timmerman RD, Fernando HC. “A radiation oncologist's and thoracic surgeon's view on the role of stereotactic ablative radiotherapy for operable lung cancer.” Seminars in thoracic and cardiovascular surgery (2013). PMID: 23800524 ↗

    L5OTHERCited in: Special Populations: Operable vs. Inoperable Patients
  3. [3]

    Pennathur A, Lanuti M, Merritt RE et al.. “Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer.” Seminars in thoracic and cardiovascular surgery (2025). PMID: 39672521 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  4. [4]

    Guckenberger M, Andratschke N, Dieckmann K et al.. “ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2017). PMID: 28687397 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  5. [5]

    Howington JA, Blum MG, Chang AC et al.. “Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.” Chest (2013). PMID: 23649443 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  6. [6]

    Guckenberger M, Andratschke N, Alheit H et al.. “Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer.” Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2014). PMID: 24052011 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  7. [7]

    Videtic GM, Chang JY, Chetty IJ et al.. “ACR appropriateness Criteria® early-stage non-small-cell lung cancer.” American journal of clinical oncology (2014). PMID: 25180631 ↗

    L1cGUIDELINECited in: Guidelines and Resources

Revision History

All updates applied to this page

Loading revisions…